$Brainstorm Cell Therapeutics(BCLI.US$
BCLI Insider Trades
INSIDER NAME: Chaim Lebovits
INSIDER POSITION: President & CEO
FILING DATE: 06/05/2024 ET/
BUY/SELL: buy
STOCK/OPTION: stocks
SHARES: 66.3K
SHARES CHANGE: 6.67%
PRICE: $0.37
COST: $24,816.09
FINAL SHARE:1.06M
BCLI Insider Trades
INSIDER NAME: Chaim Lebovits
INSIDER POSITION: President & CEO
FILING DATE: 06/05/2024 ET/
BUY/SELL: buy
STOCK/OPTION: stocks
SHARES: 66.3K
SHARES CHANGE: 6.67%
PRICE: $0.37
COST: $24,816.09
FINAL SHARE:1.06M
1
$Boxlight(BOXL.US$
The earnings report is pretty bad compared to other years.. so expect a increase in the price because the stock market is retarded.
The earnings report is pretty bad compared to other years.. so expect a increase in the price because the stock market is retarded.
2
$Serve Robotics(SERV.US$
Uber Technologies Inc Reports 15.2% Stake in Serve Robotics Inc as of May 8 - SEC Filing
Uber Technologies Inc Reports 15.2% Stake in Serve Robotics Inc as of May 8 - SEC Filing
$NANO Nuclear Energy(NNE.US$
Listing DateMay 8, 2024/Issue Price4.0
Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.
Founded2022CEOMr. James WalkerMarketNASDAQEmployees27Securities TypeOrdinary SharesFiscal Yea...
Listing DateMay 8, 2024/Issue Price4.0
Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.
Founded2022CEOMr. James WalkerMarketNASDAQEmployees27Securities TypeOrdinary SharesFiscal Yea...
2
$Draganfly(DPRO.US$
San Diego, CA., May 7, 2024 – Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer is excited to announce the launch of its newest product, the FlexForce Modular FPV UAV System, available exclusively to Government & Military buyers following a FPV UAV Demonstration and Training.
Designed to meet the rigorous demands of Government and Defense aeri...
San Diego, CA., May 7, 2024 – Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer is excited to announce the launch of its newest product, the FlexForce Modular FPV UAV System, available exclusively to Government & Military buyers following a FPV UAV Demonstration and Training.
Designed to meet the rigorous demands of Government and Defense aeri...
$Jet.AI(JTAI.US$
LAS VEGAS, May 08, 2024 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI" or the "Company") (NASDAQ: JTAI), an innovative private aviation and artificial intelligence ("AI") company, today announced it has officially launched its national jet card program.
The program offers all categories of private jet for service within the continental U.S., guaranteed rates, guaranteed availability, and a 48-hour call out. Program highlights include an optional escrow, and only 44 peak day...
LAS VEGAS, May 08, 2024 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI" or the "Company") (NASDAQ: JTAI), an innovative private aviation and artificial intelligence ("AI") company, today announced it has officially launched its national jet card program.
The program offers all categories of private jet for service within the continental U.S., guaranteed rates, guaranteed availability, and a 48-hour call out. Program highlights include an optional escrow, and only 44 peak day...
$Phio Pharmaceuticals(PHIO.US$
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
Preclinical studies demonstrate:
The data, authored by Melissa Maxwell, Lind...
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
Preclinical studies demonstrate:
The data, authored by Melissa Maxwell, Lind...
$Biorestorative Therapies(BRTX.US$
MELVILLE, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced its development of a novel exosome-based biologic program targeting obesity.
BioRestorative currently anticipates initiating the formal U.S. Food and Drug Administration ("FDA") process for this ThermoStem®-based therapeutic candidate by...
MELVILLE, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced its development of a novel exosome-based biologic program targeting obesity.
BioRestorative currently anticipates initiating the formal U.S. Food and Drug Administration ("FDA") process for this ThermoStem®-based therapeutic candidate by...
$Veru Inc(VERU.US$
Veru Reports Fiscal 2024 Second Quarter Financial Results and
Progress of its Enobosarm High Quality Weight Loss Clinical Program
—Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for highquality weight loss is actively enrolling—
—Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDswith significant relevant medical, clinical and scientific expertise—
—Company to present this month at upcoming American Ass...
Veru Reports Fiscal 2024 Second Quarter Financial Results and
Progress of its Enobosarm High Quality Weight Loss Clinical Program
—Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for highquality weight loss is actively enrolling—
—Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDswith significant relevant medical, clinical and scientific expertise—
—Company to present this month at upcoming American Ass...
3
Sean ParkerOP : thank you sir! thanks to you, I successfully scaled out. I'm still holding some but you telling me about that got me 4 profitable sales instead of one minor one lol